Program
Risperidone
Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.
Drug pageRisperidone: every studyMany companies study it; this page follows only the 99 they lead. All 262 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 670 open or running | phase 4since Jun 4, 2003 | May 2, 2002 | none ahead |
| Rovi Pharmaceuticals Laboratoriesits history only | 50 open or running | phase 3since May 12, 2017 | Feb 5, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 3since Apr 9, 2018 | Jan 26, 2009 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 4since Nov 14, 2005 | May 2, 2002 | none ahead |
| Luye Pharma Groupits history only | 30 open or running | phase 1since Jan 31, 2014 | Jan 31, 2014 | none ahead |
| Lyndraits history only | 30 open or running | phase 3since Mar 9, 2023 | Sep 16, 2020 | none ahead |
| Braeburn Pharmaceuticalsits history only | 20 open or running | phase 3since May 11, 2016 | Jan 7, 2016 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| IPCA Laboratoriesits history only | 20 open or running | phase 1since Jun 11, 2012 | Jun 11, 2012 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 15, 2010 | Oct 15, 2010 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Jul 10, 2009 | Jul 10, 2009 | none ahead |
| Delporits history only | 10 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Indivior Pharmaceuticalsits history only | 10 open or running | phase 4since May 30, 2019 | May 30, 2019 | none ahead |
| Pfizerits history only | 10 open or running | no phasesince Sep 9, 2005 | Sep 9, 2005 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 2since Oct 23, 2023 | Oct 23, 2023 | none ahead |
Also a collaborator on its studies: Otsuka and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 19, 2004.
- Jul 6, 2009Phase 4 study in SchizophreniaNCT00934635 · 2 enrolled · Germany
- Sep 25, 2009Phase 1 study in Bipolar DisorderNCT00986336 · 56 enrolled
- Oct 8, 2009Phase 4 study in SchizophreniaNCT00992407 · 75 enrolled · Korea, Republic of
- Jan 14, 2010Phase 4 study in SchizophreniaNCT01050582 · 244 enrolled · United States, Belgium, Germany and more
- May 25, 2012Phase 1 study in HealthyNCT01607762 · 31 enrolled · Belgium
- Jun 19, 2012Phase 3 study in Autistic DisorderNCT01624675 · 39 enrolled · Japan
- Nov 9, 2012Phase 4 study in SchizophreniaNCT01726335 · 53 enrolled · Brazil
- Mar 22, 2013Phase 4 study in SchizophreniaNCT01855074 · 80 enrolled
- Feb 17, 2014Phase 1 study in Psychotic DisordersNCT02087579 · 305 enrolled · United States, Argentina, Belgium and more
- Jun 2, 2015Phase 2 study in SchizophreniaNCT02462473 · 9 enrolled · United States
- Nov 2, 2015Phase 1 study in ImmunoassayNCT02634463 · 81 enrolled · Belgium
- Jul 14, 2017Phase 1 study in HealthyNCT03220867 · China
- Oct 18, 2018Phase 4 study in SchizophreniaNCT03713658 · 34 enrolled · Rwanda
- Jun 22, 2021Phase 4 study in SchizophreniaNCT04940039 · 93 enrolled · Rwanda
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
Studies
The newest 60 of 67 Johnson & Johnson leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04940039Schizophrenia · Rwanda | 4 | Completed | Apr 16, 2024 | 93 |
| NCT03713658Schizophrenia · Rwanda | 4 | Completed | Dec 2, 2019 | 34 |
| NCT03220867Healthy · China | 1 | Withdrawn | Jan 2, 2018 | 0 |
| NCT02634463Immunoassay · Belgium | 1 | Completed | Nov 9, 2016 | 81 |
| NCT02462473Schizophrenia · United States | 2 | Terminated | Jan 2016 | 9 |
| NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more | 1 | Completed | Oct 2014 | 305 |
| NCT01855074Schizophrenia | 4 | Completed | Feb 2009 | 80 |
| NCT01726335Schizophrenia · Brazil | 4 | Completed | Mar 2008 | 53 |
| NCT01624675Autistic Disorder · Japan | 3 | Completed | Oct 2014 | 39 |
| NCT01607762Healthy · Belgium | 1 | Completed | Apr 2012 | 31 |
| NCT01050582Schizophrenia · United States, Belgium, Germany and more | 4 | Completed | Jul 2011 | 244 |
| NCT00992407Schizophrenia · Korea, Republic of | 4 | Completed | Dec 2010 | 75 |
| NCT00986336Bipolar Disorder | 1 | Completed | 56 | |
| NCT00934635Schizophrenia · Germany | 4 | Terminated | Dec 2009 | 2 |
| NCT00645502Schizophrenia | 1 | Completed | 40 | |
| NCT00576732Autistic Disorder · United States | 4 | Completed | Sep 2009 | 96 |
| NCT00558298Schizophrenia | 3 | Completed | 811 | |
| NCT00535132Schizophrenia · United States, Argentina, Colombia and more | 4 | Completed | Jul 2008 | 201 |
| NCT00526877Schizophrenia · Taiwan | 4 | Completed | Jan 31, 2009 | 31 |
| NCT00495118Schizophrenia | 3 | Completed | 314 | |
| NCT00378183Psychotic Disorders | 4 | Completed | 120 | |
| NCT00378092Schizophrenia · South Africa | 4 | Completed | Mar 2010 | 33 |
| NCT00287742Alzheimer Disease | 3 | Terminated | 33 | |
| NCT00266552Conduct Disorder | 3 | Completed | 118 | |
| NCT00261508Autistic Disorder | 3 | Completed | 80 | |
| NCT00257075Bipolar Disorder | 3 | Completed | 267 | |
| NCT00254930Learning Disabilities | 3 | Completed | 19 | |
| NCT00253162Bipolar Disorder | 3 | Completed | 439 | |
| NCT00253149Bipolar Disorder | 3 | Completed | 158 | |
| NCT00253136Schizophrenia | 3 | Completed | 458 | |
| NCT00253123Dementia | 3 | Completed | 626 | |
| NCT00253110Schizophrenia | 4 | Completed | 396 | |
| NCT00250367Bipolar Disorder | 3 | Completed | 151 | |
| NCT00250354Conduct Disorder | 3 | Completed | 110 | |
| NCT00249236Bipolar Disorder | 3 | Completed | 291 | |
| NCT00249171Schizophrenia | 4 | Completed | 226 | |
| NCT00249158Dementia | 3 | Completed | 344 | |
| NCT00249145Dementia | 3 | Completed | 349 | |
| NCT00249132Schizophrenia | 3 | Completed | 523 | |
| NCT00249119Schizophrenia | 3 | Completed | 1,579 | |
| NCT00246285Schizophrenia | 3 | Completed | 381 | |
| NCT00246272Schizophrenia | 3 | Completed | 82 | |
| NCT00246246Bipolar Disorder | 3 | Completed | 48 | |
| NCT00240708Schizophrenia | 3 | Completed | 205 | |
| NCT00236587Schizophrenia | 3 | Completed | 100 | |
| NCT00236548Schizophrenia | 3 | Completed | 1 | |
| NCT00236470Attention Deficit and Disruptive Behavior Disorders | 3 | Completed | 232 | |
| NCT00236457Schizophrenia | 3 | Completed | 629 | |
| NCT00236444Attention Deficit and Disruptive Behavior Disorders | 3 | Completed | 375 | |
| NCT00236379Schizophrenia | 4 | Completed | 59 | |
| NCT00236353Schizophrenia | 3 | Completed | 86 | |
| NCT00216632Schizophrenia | 4 | Completed | Jul 2007 | 99 |
| NCT00216554Bipolar Disorder | 4 | Completed | 118 | |
| NCT00216528Schizophrenia | 4 | Completed | 527 | |
| NCT00210691Schizophrenia | 3 | Completed | 273 | |
| NCT00132678Bipolar Disorder · United States, Austria, India and more | 3 | Completed | Oct 2007 | 559 |
| NCT00097032Bipolar Disorder | 3 | Completed | 30 | |
| NCT00095134Depressive Disorder, Major · United States | 3 | Completed | 630 | |
| NCT00094926Bipolar Disorder | 3 | Completed | 275 | |
| NCT00088075Schizophrenia | 3 | Completed | 160 |
How it is read
Names in the registry
- “risperidone”, 40 entries
- “Risperidone”, 34 entries
- “Oral risperidone”, 5 entries
- “Risperidone ISM 100 mg”, 3 entries
- “LY03004”, 3 entries
Codes read as this program: LYN005.
Conditions, from the studies’ own filings
- Schizophrenia, 63 studies
- Bipolar Disorder, 12 studies
- Psychotic Disorders, 3 studies
- Autistic Disorder, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.